EP0832219A2 - Chimeric leptin fused to immunoglobulin domain and use - Google Patents
Chimeric leptin fused to immunoglobulin domain and useInfo
- Publication number
- EP0832219A2 EP0832219A2 EP96917584A EP96917584A EP0832219A2 EP 0832219 A2 EP0832219 A2 EP 0832219A2 EP 96917584 A EP96917584 A EP 96917584A EP 96917584 A EP96917584 A EP 96917584A EP 0832219 A2 EP0832219 A2 EP 0832219A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- leptin
- chimera
- human
- variant
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title claims abstract description 36
- 229940039781 leptin Drugs 0.000 title claims abstract description 34
- 102000016267 Leptin Human genes 0.000 title claims abstract description 31
- 108010092277 Leptin Proteins 0.000 title claims abstract description 31
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 22
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 22
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 208000008589 Obesity Diseases 0.000 claims abstract description 20
- 235000020824 obesity Nutrition 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 108020004414 DNA Proteins 0.000 claims description 50
- 150000001875 compounds Chemical class 0.000 claims description 40
- 239000002773 nucleotide Substances 0.000 claims description 34
- 125000003729 nucleotide group Chemical group 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 27
- 102000053602 DNA Human genes 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 21
- 102000037865 fusion proteins Human genes 0.000 claims description 17
- 108020001507 fusion proteins Proteins 0.000 claims description 17
- 239000002537 cosmetic Substances 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- 101001063991 Homo sapiens Leptin Proteins 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 8
- 102000049953 human LEP Human genes 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000001131 transforming effect Effects 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 36
- 102000004169 proteins and genes Human genes 0.000 abstract description 23
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 7
- 206010020772 Hypertension Diseases 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 238000011321 prophylaxis Methods 0.000 abstract description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 3
- 230000002035 prolonged effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 230000037432 silent mutation Effects 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 229930195712 glutamate Natural products 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical class N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to a novel compound being a novel chimeric protein, to a process for the preparation of such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound in medicine, especially for the treatment of obesity and associated diseases.
- European Patent Application, Publication number 0 464 533 discloses fusion proteins comprising various portions of the constant region of immunoglobulin molecules together with another human protein or part thereof.
- European Patent Application, Publication number 0 297 882 discloses fusion proteins comprising various portions of the plasminogen molecule with part of another human protein.
- Zhang et al. (Nature: 372, 425 - 432; 1994) describe the positional cloning of a mouse obese gene and its human homologue.
- the sequence of the Open Reading Frame (ORF) of the mouse gene predicts a polypeptide of 167 amino acids and Zhang et al. predicted the presence of a signal sequence which would lead to the production of a mature protein of 146 residues.
- the human homologue was disclosed as having a similar size of 146 amino acids for the mature protein.
- a pa ⁇ icularly desirable property of an obesity agent is a clearance rate in humans commensurate with patient acceptable treatment regimens, especially regimens for injectable therapies.
- Zhang et al. do not disclose information relating to the clearance rate of the active molecule in either mouse or humans.
- leptin must interact with one or more receptors in the brain.
- chimeric derivatives of leptin which surprisingly, despite their large molecular size, have good pharmacological activity combined with prolonged clearance rates. These chimeric derivatives of leptin are therefore indicated to be particularly useful for the treatment or prophylaxis of obesity and for the treatment or prophylaxis of diseases and conditions associated with obesity, such as atherosclerosis, hypertension and, especially, Type II diabetes. In pa ⁇ icular these compounds are considered to be useful for administration by injection. These compounds are also considered to be useful in cosmetic treatments for the improvement of body appearance.
- the invention provides a chimeric leptin or a chimeric mutant or derivative of leptin.
- a chimeric leptin is a protein comprising leptin or a mutant or variant thereof fused to a human immunoglobulin domain or a mutant or variant thereof.
- the chimeric protein comprises one human immunoglobulin domain.
- the human immunoglobulin domain is fused to the C-terminus of leptin.
- One favoured human immunoglobulin is an human immunoglobulin Fc domain.
- An example of a human immunoglobulin Fc domain is an IgG4PE variant in pa ⁇ icular IgG4 hinge-CH 2 -CH 3 .PE.
- Other examples are IgG4, IgGl and IgGlGT, in particular the hinge-CH2-CH3 region in each case.
- mutant or variant used with respect to a pa ⁇ icular protein encompasses any molecule such as a truncated or other derivative of the relevant protein which retains substantially the same activity in humans as the relevant protein.
- Such other derivatives can be prepared by the addition, deletion, substitution, or rearrangement of amino acids or by chemical modifications thereof.
- the immunoglobulin may be of any subclass (IgG, IgM, IgA, IgE), but is preferably IgG, such as IgGl, IgG3 or IgG4.
- the said constant domain(s) or fragment thereof may be derived from the heavy or light chain or both.
- the invention encompasses mutations in the immunoglobulin component which eliminate undesirable prope ⁇ ies of the native immunoglobulin, such as Fc receptor binding and/or introduce desirable prope ⁇ ies such as stability. For example, Angal S., King D.J., Bodmer M.W., Turner A., Lawson A.D.G., Robe ⁇ s G., Pedley B.
- EP0307434 discloses various mutations including an L to E mutation at residue 248 (Kabat numbering) in IgG.
- the constant domain(s) or fragment thereof is preferably the whole or a substantial pan of the constant region of the heavy chain of human IgG.
- the IgG component suitably comprises the CH2 and CH3 domains and the hinge region including cysteine residues contributing to inter-heavy chain disulphide bonding.
- the IgG component when the IgG component is derived from IgG4 it includes cysteine residues 8 and 11 of the IgG4 hinge region (Pinck J.R. and Milstein C, Nature vo!216pp941-942, 1967).
- the IgG4 component consists of amino acids co ⁇ esponding to residues 1-12 of the hinge, 1-110 of CH2 and 1-107 of CH3 of IgG4 described by Ellison J., Buxbaum J. and Hood L., DNA vollppl 1-18, 1981.
- residue 10 of the hinge is altered from serine (S) in the wild type to proline (P) and residue 5 of CH2 (residue 248, Kabat numbering) is altered from leucine (L) in the wild type to glutamate (E).
- DNA polymers which encode mutants or variants of the human immunoglobulin may be prepared by site-directed mutagenesis of the cDNA which codes for the required protein by conventional methods such as those described by G. Winter et al in Nature 1982, 299, 756-758 or by Zoller and Smith 1982; Nucl. Acids Res., 10, 6487-6500, or deletion mutagenesis such as described by Chan and Smith in Nucl. Acids Res., 1984, 12, 2407-2419 or by G. Winter er al in Biochem. Soc. Trans., 1984; 12, 224-225 or polymerase chain reaction such as described by Mikaelian and Sergeant in Nucleic Acids Research, 1992, 20, 376.
- 'compound of the invention' or 'compounds of the invention' relates to the above mentioned chimera.
- the invention provides a process for preparing a compound according to the invention which process comprises expressing DNA encoding said compound in a recombinant host cell and recovering the product.
- the DNA polymer comprising a nucleotide sequence that encodes the compound also forms pan of the invention.
- the process of the invention may be performed by conventional recombinant techniques such as described in Maniatis et. al., Molecular Cloning - A Laboratory Manual; Cold Spring Harbor, 1982 and DNA Cloning vols I, II and III (D.M. Glover ed., IRL Press Ltd).
- the process may comprise the steps of: i) preparing a replicable expression vector capable, in a host cell, of expressing a
- DNA polymer comprising a nucleotide sequence that encodes said compound; ii) transforming a host cell with said vector; iii) culturing said transformed host cell under conditions permitting expression of said DNA polymer to produce said compound; and iv) recovering said compound.
- the invention also provides a process for preparing the DNA polymer by the condensation of appropriate mono-, di- or oligomeric nucleotide units.
- the preparation may be carried out chemically, enzymatically, or by a combination of the two methods, in vitro or in vivo as appropriate.
- the DNA polymer may be prepared by the enzymatic ligation of appropriate DNA fragments, by conventional methods such as those described by D. M. Robe ⁇ s et al in Biochemistry 1985, 24, 5090-5098.
- the DNA fragments may be obtained by digestion of DNA containing the required sequences of nucleotides with appropriate restriction enzymes, by chemical synthesis, by enzymatic polymerisation on DNA or RNA templates, or by a combination of these methods.
- Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70°C, generally in a volume of 50 ⁇ l or less with 0.1- lO ⁇ g DNA.
- Enzymatic polymerisation of DNA may be carried out in vitro using a DNA polymerase such as DNA polymerase I (Klenow fragment) in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37°C, generally in a volume of 50 ⁇ l or less.
- a DNA polymerase such as DNA polymerase I (Klenow fragment) in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37°C, generally in a volume of 50 ⁇ l or less.
- Enzymatic ligation of DNA fragments may be carried out using a DNA ligase such as T4 DNA ligase in an appropriate buffer at a temperature of 4°C to ambient, generally in a volume of 50 ⁇ l or less.
- a DNA ligase such as T4 DNA ligase in an appropriate buffer at a temperature of 4°C to ambient, generally in a volume of 50 ⁇ l or less.
- the chemical synthesis of the DNA polymer or fragments may be carried out by conventional phosphotriester, phosphite or phosphoramidite chemistry, using solid phase techniques such as those described in 'Chemical and Enzymatic Synthesis of Gene Fragments - A Laboratory Manual' (ed. H.G. Gassen and A. Lang), Verlag Chemie, Weinheim (1982),or in other scientific publications, for example M.J. Gait, H.W.D. Matthes, M. Singh, B.S. Sproat, and R.C. Titmas, Nucleic Acids Research, 1982, 10, 6243; B.S. Sproat and W. Bannwa ⁇ h, Tetrahedron Letters, 1983, 24, 5771; M.D.
- the DNA polymer is preferably prepared by ligating two or more DNA molecules which together comprise a DNA sequence encoding the compound.
- a particular process in accordance with the invention comprises ligating a first DNA molecule encoding a said leptin or variant and a second DNA molecule encoding a said immunoglobulin domain or fragment thereof.
- the DNA molecules may be obtained by the digestion with suitable restriction enzymes of vectors carrying the required coding sequences or by use of polymerase chain reaction technology.
- the precise structure of the DNA molecules and the way in which they are obtained depends upon the structure of the desired product.
- the design of a suitable strategy for the construction of the DNA molecule coding for the compound is a routine matter for the skilled worker in the an.
- the expression of the DNA polymer encoding the compound in a recombinant host cell may be carried out by means of a replicable expression vector capable, in the host cell, of expressing the DNA polymer.
- the expression vector is novel and also forms pan of the invention.
- the replicable expression vector may be prepared in accordance with the invention, by cleaving a vector compatible with the host cell to provide a linear DNA segment having an intact replicon, and combining said linear segment with one or more DNA molecules which, together with said linear segment, encode the compound, under ligating conditions.
- the ligation of the linear segment and more than one DNA molecule may be carried out simultaneously or sequentially as desired.
- the DNA polymer may be preformed or formed during the construction of the vector, as desired.
- the choice of vector will be determined in pan by the host cell, which may be prokaryotic, such as E. coli, or eukaryotic, such as mouse C127, mouse myeloma, Chinese hamster ovary, Cosl or Hela cells, fungi e.g. filamentous fungi or unicellular yeast or an insect cell such as Drosophila.
- the host cell may also be a transgenic animal.
- a preferred host cell is Cosl.
- Suitable vectors include plasmids, bacteriophages, cosmids and recombinant viruses derived from, for example, baculoviruses, vaccinia or Semliki Forest virus.
- the preparation of the replicable expression vector may be carried out conventionally with appropriate enzymes for restriction, polymerisation and ligation of the DNA, by procedures described in, for example, Maniatis ej ai., cited above. Polymerisation and ligation may be performed as described above for the preparation of the DNA polymer. Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70°C, generally in a volume of 50 ⁇ l or less with 0.1-10 ⁇ g DNA.
- the recombinant host cell is prepared, in accordance with the invention, by transforming a host cell with a replicable expression vector of the invention under transforming conditions.
- Suitable transforming conditions are conventional and are described in, for example, Maniatis et al., cited above, or "DNA Cloning" Vol. II, D.M. Glover ed., IRL Press Ltd, 1985.
- a bacterial host such as E. coli may be treated with a solution of CaCl2 (Cohen et al, Proc. Nat. Acad. Sci., 1973, 69, 2110) or with a solution comprising a mixture of RbCl, MnCl2, potassium acetate and glycerol, and then with 3-[N-morpholino]- propane-sulphonic acid, RbCl and glycerol.
- Mammalian cells in culture may be transformed by calcium co-precipitation of the vector DNA onto the cells.
- the invention also extends to a host cell transformed or transfected with a replicable expression vector of the invention.
- Culturing the transformed host cell under conditions permitting expression of the DNA polymer is carried out conventionally, as described in, for example, Maniatis et al and "DNA Cloning" cited above.
- the cell is supplied with nutrient and cultured at a temperature below 45°C.
- the expression product is recovered by conventional methods according to the host cell.
- the host cell is bacterial, such as E. coli it may be lysed physically, chemically or enzymatically and the protein product isolated from the resulting lysate. If the product is to be secreted from the bacterial cell it may be recovered from the periplasmic space or the nutrient medium. Where the host cell is mammalian, the product may generally be isolated from the nutrient medium.
- the DNA polymer may be assembled into vectors designed for isolation of stable transformed mammalian cell lines expressing the product; e.g. bovine papillomavirus vectors or amplified vectors in Chinese hamster ovary cells (DNA cloning Vol.II D.M. Glover ed. IRL Press 1985; Kaufman, R.J. ⁇ i al., Molecular and Cellular Biology 5, 1750-1759, 1985; Pavlakis G.N. and Hamer, D.H., Proceedings of the National Academy of Sciences (USA) 80, 397-401, 1983; Goeddel, DN. et al., European Patent Application No. 0093619, 1983).
- bovine papillomavirus vectors or amplified vectors in Chinese hamster ovary cells
- the activity of the chimeric leptin is determined by injecting it intraperitoneally, intravenously or subcutaneously into test animals such as rodents, for example mice or rats, or primates, for example rhesus monkeys.
- test animals such as rodents, for example mice or rats, or primates, for example rhesus monkeys.
- the test animals are preferably overweight or obese animals that have been made overweight by feeding them on a high fat or other palatable diet, or have acquired fat through the ageing process.
- the ideal strain is the generically obese (ob/ob) mouse.
- the effect of the active compound is seen as a reduction in food intake or increase in metabolic rate or oxygen consumption.
- Clearance rates are determined by conventional plasma assay using ob-antibodies, for example ELISA methodology.
- the compounds of the present invention have useful pharmaceutical prope ⁇ ies, in pa ⁇ icular anti obesity activity and also for the treatment of diseases associated with obesity, such as atherosclerosis, hype ⁇ ension and, especially, Type LI diabetes.
- the compound will normally be employed in the form of a pharmaceutical composition in association with a human pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will depend on the mode of administration.
- the active compound may be formulated for administration by any suitable route and is preferably in unit dosage form.
- the composition is suitable for oral, rectal, topical, parenteral, intravenous or intramuscular administration or through the respiratory tract. Preparations may be designed to give slow release of the active ingredient.
- compositions of the invention may be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations such as oral or sterile parenteral solutions or suspensions. Topical formulations are also envisaged where appropriate.
- the invention therefore further provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier.
- the dosage ranges for administration of the compounds of the present invention are those to produce the desired therapeutic effect. Dosage will generally vary with age, extent or severity of the medical condition and contraindications, if any. For example in the treatment of obsity the unit dosage can vary from less than lmg to 300mg, but typically will be in the region of 1 to 20mg per dose, in one or more doses, such as one to six doses per day, such that the daily dosage is in the range 0.02-40mg/kg. Dosages and compositions for the treatment of diseases associated with obesity such as atherosclerosis, hype ⁇ ension and, especially, Type II diabetes are selected from an equivalent range to that used in the treatment of obesity.
- compositions suitable for injection may be in the form of solutions, suspensions or emulsions, or dry powders which are dissolved or suspended in a suitable vehicle prior to use.
- Fluid unit dosage forms are prepared utilising the compound and a pyrogen-free sterile vehicle.
- the compound depending on the vehicle and concentration used, can be either dissolved or suspended in the vehicle. Solutions may be used for all forms of parenteral administration, and are panicularly used for intravenous infection. In preparing solutions the compound can be dissolved in the vehicle, the solution being made isotonic if necessary by addition of sodium chloride and sterilised by filtration through a sterile filter using aseptic techniques before filling into suitable sterile vials or ampoules and sealing. Alternatively, if solution stability is adequate, the solution in its sealed containers may be sterilised by autoclaving.
- Advantageously additives such as buffering, solubilising, stabilising, preservative or bactericidal, suspending or emulsifying agents and/or local anaesthetic agents may be dissolved in the vehicle.
- Dry powders which are dissolved or suspended in a suitable vehicle prior to use may be prepared by filling pre-sterilised drug substance and other ingredients into a sterile container using aseptic technique in a sterile area.
- the drug and other ingredients may be dissolved in an aqueous vehicle, the solution is sterilised by filtration and distributed into suitable containers using aseptic technique in a sterile area. The product is then freeze dried and the containers are sealed aseptically.
- Parenteral suspensions suitable for intramuscular, subcutaneous or intradermal injection, are prepared in substantially the same manner, except that the sterile compound is suspended in the sterile vehicle, instead of being dissolved and sterilisation cannot be accomplished by filtration.
- the compound may be isolated in a sterile state or alternatively it may be sterilised after isolation, e.g. by gamma i ⁇ adiation.
- a suspending agent for example polyvinylpyrrolidone is included in the composition to facilitate uniform distribution of the compound.
- compositions suitable for administration via the respiratory tract include aerosols, nebulisable solutions or microfine powders for insufflation. In the latter case, panicle size of less than 50 microns, especially less than 10 microns, is preferred. Such compositions may be made up in a conventional manner and employed in conjunction with conventional administration devices.
- a fu ⁇ her aspect there is provided a method of treating obesity or diseases associated with obesity, such as atherosclerosis, hype ⁇ ension and, especially, Type LT diabetes, in human or non-human mammals which comprises administering to the sufferer an effective, non-toxic amount of a compound of the invention.
- obesity or diseases associated with obesity such as atherosclerosis, hype ⁇ ension and, especially, Type LT diabetes
- Suitable non-human mammals are domestic mammals such as dogs and cats.
- the invention funher provides a compound of the invention for use as an active therapeutic substance, in pa ⁇ icular for use in treating obesity or diseases associated with obesity, such as atherosclerosis, hypertension and, especially, Type LT diabetes.
- the invention also provides the use of a compound of the invention in the manufacture of a medicament for treating obesity or diseases associated with obesity, such as atherosclerosis, hype ⁇ ension and, especially, Type LT diabetes.
- the invention also encompasses cosmetic treatments. Accordingly, there is also provided a compound of the invention for use in the cosmetic treatment of human or non-human mammals.
- a method for the cosmetic treatment of a human or non ⁇ human mammal which treatment comprises administering an effective, non-toxic amount of a compound of the invention to a human or non-human mammal in need thereof.
- Cosmetic treatment suitably includes treatment for the improvement of body appearence, such as weight reduction treatment.
- compositions of the invention including cosmetic compositions are formulated using known methods, for example those described in standard text books of pharmaceutics and cosmetics, such as Harry's Cosmeticology published by Leonard Hill Books, Remington's Pharmaceutical Sciences, the British and US Pharmacopoeias.
- the gene coding for a fusion protein comprising human leptin and the hinge-CH2-CH3 region of human IgG4 is created by recombinant DNA technology, preferably by a two-step recombinant PCR method.
- the human Ob' gene has been prepared synthetically based on the amino acid sequence of Zhang et al, and assembled in the pcDNA3 vector.
- the cDNA encoding full length human leptin, nucleotides 1-501 is joined at the 3' end to the 5' end of the hinge-CH2-CH3 region of the cDNA coding for the human IgG4 protein, shown as nucleotides 502-1188 in the DNA sequence below.
- Table 1 The encoded protein sequence of the leptin/IgG4 chimera is given in Table 2.
- Leptin 1-167 (numbering as Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold & J. Friedman. Nature 372:425-432), and IgG4 hinge-CH2-CH3 168-396 (sequence as Kabat).
- the fusion protein was expressed transiently in Cosl cells using the pCDN vector system, as described in Intemationai Patent Application Publication number WO 96/04388.
- the mature protein was exponed from the cells into the culture medium and was detected by anti-leptin antibody. It was shown to to have a size consistent with the predicted structure by Western blotting analysis under both reducing and nonreducing conditions.
- DNA coding for fusion protein ob l-167/IgG4 hinge-CH2-CH3 PE variant The gene coding for a fusion protein comprising the human Ob' protein and the Hinge-CH2-CH3 region of human IgG4 PE (a form of IgG4 mutated as below) is created by recombinant DNA technology, preferably by a two-step recombinant PCR method.
- the cDNA coding for the complete human leptin, amino acids l-167(numbering as Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold & J. Friedman. Nature 372: 425-432) is joined at the 3' end to the 5' end of the hinge-CH2-CH3 region of the cDNA coding for the human IgG4 (PE variant) protein, shown as amino acids 168-396 in the protein sequence below.
- the human Ob' gene has been prepared synthetically based on the amino acid sequence of Zhang et al, and assembled in the pcDNA3 vector.
- the encoded protein sequence is given in Table 2.
- IgG4 heavy chain PE variant Human IgG4 heavy chain PE variant.
- residue 10 of the hinge is altered from serine (S) in the wild type to proline (P) and residue 5 of CH2 (residue 248, Kabat numbering) is altered from leucine (L) in the wild type to glutamate (E).
- Angal S. King D.J., Bodmer M.W., Turner A., Lawson A.D.G., Robe ⁇ s G., Pedley B. and Adair R., Molecular Immunology vol30ppl05-108, 1993, describe an IgG4 molecule where residue 241 (Kabat numbering) is altered from serine to proline. This change increases the serum half-life of the IgG4 molecule.
- the IgG4 PE variant was created using PCR mutagenesis on the synthetic human IgG4 heavy chain cDNA.
- the sequence of the IgG4 PE variant is described in Table 1.
- the residues of the IgG4 nucleotide sequence which were altered to make the PE variant are as follows: referring to Table 1 : residue 322 has been altered to "C” in the PE variant from "T” in the wild type; residue 333 has been altered to "G” in the PE variant from "A” in the wild type; and residues 343-344 have been altered to "GA” in the PE variant from "CT” in the wild type.
- the fusion protein was expressed transiently in Cosl cells using the pCDN vector system, as described in International Patent Application Publication number WO 96/04388.
- the mature protein was exponed from the cells into the culture medium and was detected by anti-leptin antibody. It was shown to to have a size consistent with the predicted structure by Western blotting analysis under both reducing and nonreducing conditions.
- Table 3 DNA sequence of IgG4 PE variant, 984bp
- Table3A DNAsequenceofob/IgG4PEchimera, 1188bp ATGCATTGGGGAACCCTGTGCGGATTCTTGTGGCTTTGGCCCTATCTTTTCTATGTCCAA
- the gene coding for a fusion protein comprising human leptin and the hinge-CH2-CH3 region of human IgGl is created by recombinant DNA technology, preferably by a two-step recombinant PCR method.
- the human 'ob' gene has been prepared synthetically based on the amino acid sequence of Zhang et al, and assembled in the pcDNA3 vector.
- the encoded protein sequence of the leptin/IgGl chimera is given in Table 2.
- Leptin 1-167 (numbering asY. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold & J. Friedman. Nature 372: 425-432) and IgGl hinge-CH2-CH3 shown as amino acids 168-399.
- the gene coding for the human IgGl contains a number of nucleotide substitutions compared to the IgGl molecule described by Ellison J.W., Berson B.J. and Hood L.E., Nucleic Acids Research vol 10 No. 13 pp4071-4079, 1982.
- the IgGl nucleotides which differ from the Ellison J.W. et al published sequence and the resulting amino acid substitutions are as follows ( nucleotide numbering as in table 1)
- nucleotide 513 is "G” in this variant compared to "T” in the Ellison et al sequence (silent mutation)
- nucleotides 514-516 are "GCC” in this variant compared to "TGT” in the Ellison et al sequence (resulting in substitution of Ala for Cys in this variant, amino acid 172 in table 2)
- nucleotide 759 is "T” in this variant compared to "G” in the Ellison et al sequence
- nucleotide 924 is "G” in this variant compared to "T” in the Ellison et al sequence (resulting in substitution of Glu for Asp in this variant, amino acid 308 in table2)
- nucleotide 928 is "A” in this variant compared to "C” in the Ellison et al sequence (resulting in substitution of Met for Val in this variant, amino acid 310 in table 2)
- nucleotide 1077 is "T” in this variant compared to "C” in the Ellison et al sequence (silent mutation)
- nucleotide 1197 is "G" in this variant compared to "A” in the Ellison et al sequence (silent mutation)
- the fusion protein was expressed transiently in Cosl cells using the pCDN vector system, as described in International Patent Application Publication number WO 96/04388.
- the mature protein was exponed from the cells into the culture medium and was detected by anti-leptin antibody. It was shown to to have a size consistent with the predicted structure by Western blotting analysis under both reducing and nonreducing conditions.
- the gene coding for a fusion protein comprising human leptin and the hinge-CH2-CH3 region of human IgGl with a 'GT' two amino acid linker between the two parts of the fusion molecule, is created by recombinant DNA technology, preferably by a two-step recombinant PCR method.
- the human 'ob' gene has been prepared synthetically based on the amino acid sequence of Zhang et al, and assembled in the pcDNA3 vector.
- the cDNA encoding the full length human leptin (nucleotides 1-501) is joined at the 3' end to the 5' end of the hinge-CH2-CH3 region of the IgGl cDNA (nucleotides 508-1203).
- the two amino acid linker between the two pans of the fusion is encoded by the nucleotide sequence GGTACC (502-507). See Table 1.
- the encoded protein sequence of the leptin/LgG 1 (GT) chimera is given in Table 2.
- the gene coding for the human IgGl contains a number of nucleotide substitutions compared to the IgGl molecule described by Ellison J.W., Berson B.J. and Hood L.E., Nucleic Acids Research vol 10 No. 13 pp4071-4079, 1982.
- the IgGl nucleotides which differ from the Ellison J.W. et al published sequence and the resulting amino acid substitutions are as follows ( nucleotide numbering as in table 1)
- nucleotide 519 is "G” in this variant compared to "T” in the Ellison et al sequence (silent mutation)
- nucleotides 520-522 are "GCC” in this variant compared to "TGT” in the Ellison et al sequence (resulting in substitution of Ala for Cys in this variant, amino acid 174 in table 2)
- nucleotide 759 is "T” in this variant compared to "G” in the Ellison et al sequence (silent mutation)
- nucleotide 924 is "G” in this variant compared to "T” in the Ellison et al sequence (resulting in substitution of Glu for Asp in this variant, amino acid 308 in table2)
- nucleotide 928 is "A” in this variant compared to "C” in the Ellison et al sequence (resulting in substitution of Met for Val in this variant, amino acid 310 in table 2)
- nucleotide 1077 is "T” in this variant compared to "C” in the Ellison et al sequence
- nucleotide 1197 is "G" in this variant compared to "A” in the Ellison et al sequence
- the fusion protein was expressed transiently in Cosl cells using the pCDN vector system, as described in International Patent Application Publication number WO 96/04388.
- the mature protein was exponed from the cells into the culture medium and was detected by anti-leptin antibody. It was shown to to have a size consistent with the predicted structure by Westem blotting analysis under both reducing and nonreducing conditions.
- VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Chimeric leptin which are proteins comprising leptin or a mutant or a variant thereof fused to a human immunogobulin domain. One favoured immunoglobulin domain is the human immunoglobulin Fc domain. The chimeric derivatives of leptin have, despite their large molecular size, good pharmacological activity combined with prolonged clearance rates. These derivatives of leptin are therefore indicated to be particularly useful for the treatment or prophylaxis of obesity or diseases and conditions associated with obesity such as atherosclerosis, hypertension and type II diabetes.
Description
CHIMERIC LEPTTN FUSED TO IMMUNOGLOBULIN DOMAIN AND USE
The present invention relates to a novel compound being a novel chimeric protein, to a process for the preparation of such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound in medicine, especially for the treatment of obesity and associated diseases.
European Patent Application, Publication number 0 464 533 discloses fusion proteins comprising various portions of the constant region of immunoglobulin molecules together with another human protein or part thereof. European Patent Application, Publication number 0 297 882 discloses fusion proteins comprising various portions of the plasminogen molecule with part of another human protein.
Zhang et al. (Nature: 372, 425 - 432; 1994) describe the positional cloning of a mouse obese gene and its human homologue. The sequence of the Open Reading Frame (ORF) of the mouse gene predicts a polypeptide of 167 amino acids and Zhang et al. predicted the presence of a signal sequence which would lead to the production of a mature protein of 146 residues. The human homologue was disclosed as having a similar size of 146 amino acids for the mature protein. Zhang et al. showed the presence of a primary translation product of approximate size of 18 kilodaltons (kD) with truncation to a 16kD product on addition of microsomal membranes, consistent with the production of a pre-protein and the removal of an N-terminal signal sequence. Zhang et al also disclose the potential use of the human obese gene product (hereinafter 'leptin') in the treatment of obesity.
For effective, practical treatment of obesity a paπicularly desirable property of an obesity agent is a clearance rate in humans commensurate with patient acceptable treatment regimens, especially regimens for injectable therapies. Zhang et al. do not disclose information relating to the clearance rate of the active molecule in either mouse or humans.
The precise mechanism of action of leptin is currently unknown, however it is considered that in order to provide the observed pharmacological effects, leptin must interact with one or more receptors in the brain.
We have now discovered certain chimeric derivatives of leptin which surprisingly, despite their large molecular size, have good pharmacological activity combined with prolonged clearance rates. These chimeric derivatives of leptin are therefore indicated to be particularly useful for the treatment or prophylaxis of obesity and for the treatment or prophylaxis of diseases and conditions associated with obesity, such as atherosclerosis, hypertension and, especially, Type II diabetes. In paπicular these compounds are considered to be useful for administration by injection.
These compounds are also considered to be useful in cosmetic treatments for the improvement of body appearance.
Accordingly, the invention provides a chimeric leptin or a chimeric mutant or derivative of leptin. One particular chimeric leptin is a protein comprising leptin or a mutant or variant thereof fused to a human immunoglobulin domain or a mutant or variant thereof.
Suitably, the chimeric protein comprises one human immunoglobulin domain.
Favourably , the human immunoglobulin domain is fused to the C-terminus of leptin. One favoured human immunoglobulin is an human immunoglobulin Fc domain.
An example of a human immunoglobulin Fc domain is an IgG4PE variant in paπicular IgG4 hinge-CH2-CH3.PE. Other examples are IgG4, IgGl and IgGlGT, in particular the hinge-CH2-CH3 region in each case.
The term "mutant or variant" used with respect to a paπicular protein encompasses any molecule such as a truncated or other derivative of the relevant protein which retains substantially the same activity in humans as the relevant protein. Such other derivatives can be prepared by the addition, deletion, substitution, or rearrangement of amino acids or by chemical modifications thereof.
The immunoglobulin may be of any subclass (IgG, IgM, IgA, IgE), but is preferably IgG, such as IgGl, IgG3 or IgG4. The said constant domain(s) or fragment thereof may be derived from the heavy or light chain or both. The invention encompasses mutations in the immunoglobulin component which eliminate undesirable propeπies of the native immunoglobulin, such as Fc receptor binding and/or introduce desirable propeπies such as stability. For example, Angal S., King D.J., Bodmer M.W., Turner A., Lawson A.D.G., Robeπs G., Pedley B. and Adair R., Molecular Immunology vol30ppl05-108, 1993, describe an IgG4 molecule where residue 241 (Kabat numbering) is altered from serine to proline. This change increases the serum half-life of the IgG4 molecule. Canfield S.M. and Morrison S.L., Journal of Experimental Medicine voll73ppl483-1491, describe the alteration of residue 248 (Kabat numbering) from leucine to glutamate in IgG3 and from glutamate to leucine in mouse IgG2b. Substitution of leucine for glutamate in the former decreases the affinity of the immunoglobulin molecule concerned for the FcγRI receptor, and substitution of glutamate for leucine in the latter increases the affinity. EP0307434 discloses various mutations including an L to E mutation at residue 248 (Kabat numbering) in IgG. The constant domain(s) or fragment thereof is preferably the whole or a substantial pan of the constant region of the heavy chain of human IgG. The IgG
component suitably comprises the CH2 and CH3 domains and the hinge region including cysteine residues contributing to inter-heavy chain disulphide bonding.
For example when the IgG component is derived from IgG4 it includes cysteine residues 8 and 11 of the IgG4 hinge region (Pinck J.R. and Milstein C, Nature vo!216pp941-942, 1967). Preferably the IgG4 component consists of amino acids coπesponding to residues 1-12 of the hinge, 1-110 of CH2 and 1-107 of CH3 of IgG4 described by Ellison J., Buxbaum J. and Hood L., DNA vollppl 1-18, 1981. In one example of a suitable mutation in IgG4, residue 10 of the hinge (residue 241, Kabat numbering) is altered from serine (S) in the wild type to proline (P) and residue 5 of CH2 (residue 248, Kabat numbering) is altered from leucine (L) in the wild type to glutamate (E).
DNA polymers which encode mutants or variants of the human immunoglobulin may be prepared by site-directed mutagenesis of the cDNA which codes for the required protein by conventional methods such as those described by G. Winter et al in Nature 1982, 299, 756-758 or by Zoller and Smith 1982; Nucl. Acids Res., 10, 6487-6500, or deletion mutagenesis such as described by Chan and Smith in Nucl. Acids Res., 1984, 12, 2407-2419 or by G. Winter er al in Biochem. Soc. Trans., 1984; 12, 224-225 or polymerase chain reaction such as described by Mikaelian and Sergeant in Nucleic Acids Research, 1992, 20, 376. When used herein 'compound of the invention' or 'compounds of the invention' relates to the above mentioned chimera.
In a fuπher aspect, the invention provides a process for preparing a compound according to the invention which process comprises expressing DNA encoding said compound in a recombinant host cell and recovering the product. The DNA polymer comprising a nucleotide sequence that encodes the compound also forms pan of the invention.
The process of the invention may be performed by conventional recombinant techniques such as described in Maniatis et. al., Molecular Cloning - A Laboratory Manual; Cold Spring Harbor, 1982 and DNA Cloning vols I, II and III (D.M. Glover ed., IRL Press Ltd).
In paπicular, the process may comprise the steps of: i) preparing a replicable expression vector capable, in a host cell, of expressing a
DNA polymer comprising a nucleotide sequence that encodes said compound; ii) transforming a host cell with said vector; iii) culturing said transformed host cell under conditions permitting expression of said DNA polymer to produce said compound; and iv) recovering said compound.
The invention also provides a process for preparing the DNA polymer by the condensation of appropriate mono-, di- or oligomeric nucleotide units.
The preparation may be carried out chemically, enzymatically, or by a combination of the two methods, in vitro or in vivo as appropriate. Thus, the DNA polymer may be prepared by the enzymatic ligation of appropriate DNA fragments, by conventional methods such as those described by D. M. Robeπs et al in Biochemistry 1985, 24, 5090-5098.
The DNA fragments may be obtained by digestion of DNA containing the required sequences of nucleotides with appropriate restriction enzymes, by chemical synthesis, by enzymatic polymerisation on DNA or RNA templates, or by a combination of these methods.
Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70°C, generally in a volume of 50μl or less with 0.1- lOμg DNA.
Enzymatic polymerisation of DNA may be carried out in vitro using a DNA polymerase such as DNA polymerase I (Klenow fragment) in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37°C, generally in a volume of 50μl or less.
Enzymatic ligation of DNA fragments may be carried out using a DNA ligase such as T4 DNA ligase in an appropriate buffer at a temperature of 4°C to ambient, generally in a volume of 50μl or less.
The chemical synthesis of the DNA polymer or fragments may be carried out by conventional phosphotriester, phosphite or phosphoramidite chemistry, using solid phase techniques such as those described in 'Chemical and Enzymatic Synthesis of Gene Fragments - A Laboratory Manual' (ed. H.G. Gassen and A. Lang), Verlag Chemie, Weinheim (1982),or in other scientific publications, for example M.J. Gait, H.W.D. Matthes, M. Singh, B.S. Sproat, and R.C. Titmas, Nucleic Acids Research, 1982, 10, 6243; B.S. Sproat and W. Bannwaπh, Tetrahedron Letters, 1983, 24, 5771; M.D. Matteucci and M.H Caruthers, Tetrahedron Letters, 1980, 21, 719; M.D. Matteucci and M.H. Caruthers, Journal of the American Chemical Society, 1981, 103, 3185; S.P. Adams et al., Journal of the American Chemical Society,1983, 105, 661; N.D. Sinha, J. Biernat, J. McMannus, and H. Koester, Nucleic Acids Research, 1984, 12, 4539; and H.W.D. Matthes et al., EMBO Journal, 1984, 3, 801. Preferably an automated DNA synthesizer is employed.
The DNA polymer is preferably prepared by ligating two or more DNA molecules which together comprise a DNA sequence encoding the compound. A particular process in accordance with the invention comprises ligating a first DNA
molecule encoding a said leptin or variant and a second DNA molecule encoding a said immunoglobulin domain or fragment thereof.
The DNA molecules may be obtained by the digestion with suitable restriction enzymes of vectors carrying the required coding sequences or by use of polymerase chain reaction technology.
The precise structure of the DNA molecules and the way in which they are obtained depends upon the structure of the desired product. The design of a suitable strategy for the construction of the DNA molecule coding for the compound is a routine matter for the skilled worker in the an. The expression of the DNA polymer encoding the compound in a recombinant host cell may be carried out by means of a replicable expression vector capable, in the host cell, of expressing the DNA polymer. The expression vector is novel and also forms pan of the invention.
The replicable expression vector may be prepared in accordance with the invention, by cleaving a vector compatible with the host cell to provide a linear DNA segment having an intact replicon, and combining said linear segment with one or more DNA molecules which, together with said linear segment, encode the compound, under ligating conditions.
The ligation of the linear segment and more than one DNA molecule may be carried out simultaneously or sequentially as desired.
Thus, the DNA polymer may be preformed or formed during the construction of the vector, as desired.
The choice of vector will be determined in pan by the host cell, which may be prokaryotic, such as E. coli, or eukaryotic, such as mouse C127, mouse myeloma, Chinese hamster ovary, Cosl or Hela cells, fungi e.g. filamentous fungi or unicellular yeast or an insect cell such as Drosophila. The host cell may also be a transgenic animal.
A preferred host cell is Cosl.
Suitable vectors include plasmids, bacteriophages, cosmids and recombinant viruses derived from, for example, baculoviruses, vaccinia or Semliki Forest virus. The preparation of the replicable expression vector may be carried out conventionally with appropriate enzymes for restriction, polymerisation and ligation of the DNA, by procedures described in, for example, Maniatis ej ai., cited above. Polymerisation and ligation may be performed as described above for the preparation of the DNA polymer. Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70°C, generally in a volume of 50μl or less with 0.1-10μg DNA.
The recombinant host cell is prepared, in accordance with the invention, by transforming a host cell with a replicable expression vector of the invention under transforming conditions. Suitable transforming conditions are conventional and are described in, for example, Maniatis et al., cited above, or "DNA Cloning" Vol. II, D.M. Glover ed., IRL Press Ltd, 1985.
The choice of transforming conditions is determined by the host cell. Thus, a bacterial host such as E. coli may be treated with a solution of CaCl2 (Cohen et al, Proc. Nat. Acad. Sci., 1973, 69, 2110) or with a solution comprising a mixture of RbCl, MnCl2, potassium acetate and glycerol, and then with 3-[N-morpholino]- propane-sulphonic acid, RbCl and glycerol. Mammalian cells in culture may be transformed by calcium co-precipitation of the vector DNA onto the cells.
The invention also extends to a host cell transformed or transfected with a replicable expression vector of the invention.
Culturing the transformed host cell under conditions permitting expression of the DNA polymer is carried out conventionally, as described in, for example, Maniatis et al and "DNA Cloning" cited above. Thus, preferably the cell is supplied with nutrient and cultured at a temperature below 45°C.
The expression product is recovered by conventional methods according to the host cell. Thus, where the host cell is bacterial, such as E. coli it may be lysed physically, chemically or enzymatically and the protein product isolated from the resulting lysate. If the product is to be secreted from the bacterial cell it may be recovered from the periplasmic space or the nutrient medium. Where the host cell is mammalian, the product may generally be isolated from the nutrient medium.
The DNA polymer may be assembled into vectors designed for isolation of stable transformed mammalian cell lines expressing the product; e.g. bovine papillomavirus vectors or amplified vectors in Chinese hamster ovary cells (DNA cloning Vol.II D.M. Glover ed. IRL Press 1985; Kaufman, R.J. ≤i al., Molecular and Cellular Biology 5, 1750-1759, 1985; Pavlakis G.N. and Hamer, D.H., Proceedings of the National Academy of Sciences (USA) 80, 397-401, 1983; Goeddel, DN. et al., European Patent Application No. 0093619, 1983).
The activity of the chimeric leptin is determined by injecting it intraperitoneally, intravenously or subcutaneously into test animals such as rodents, for example mice or rats, or primates, for example rhesus monkeys. In order to maximise activity, the test animals are preferably overweight or obese animals that have been made overweight by feeding them on a high fat or other palatable diet, or have acquired fat through the ageing process. In the case of mice, however, the ideal strain is the generically obese (ob/ob) mouse. The effect of the active compound is seen as a reduction in food intake or increase
in metabolic rate or oxygen consumption. Multiple injections of the active compound - at most twice daily - over a period of a week for rodents or a month for primates, also cause a reduction in body weight and in the size of discrete adipose tissue depots.
Clearance rates are determined by conventional plasma assay using ob-antibodies, for example ELISA methodology.
As indicated above the compounds of the present invention have useful pharmaceutical propeπies, in paπicular anti obesity activity and also for the treatment of diseases associated with obesity, such as atherosclerosis, hypeπension and, especially, Type LI diabetes. In use the compound will normally be employed in the form of a pharmaceutical composition in association with a human pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will depend on the mode of administration. The active compound may be formulated for administration by any suitable route and is preferably in unit dosage form. Advantageously, the composition is suitable for oral, rectal, topical, parenteral, intravenous or intramuscular administration or through the respiratory tract. Preparations may be designed to give slow release of the active ingredient.
The compositions of the invention may be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations such as oral or sterile parenteral solutions or suspensions. Topical formulations are also envisaged where appropriate.
The invention therefore further provides a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier.
The dosage ranges for administration of the compounds of the present invention are those to produce the desired therapeutic effect. Dosage will generally vary with age, extent or severity of the medical condition and contraindications, if any. For example in the treatment of obsity the unit dosage can vary from less than lmg to 300mg, but typically will be in the region of 1 to 20mg per dose, in one or more doses, such as one to six doses per day, such that the daily dosage is in the range 0.02-40mg/kg. Dosages and compositions for the treatment of diseases associated with obesity such as atherosclerosis, hypeπension and, especially, Type II diabetes are selected from an equivalent range to that used in the treatment of obesity.
Compositions suitable for injection may be in the form of solutions, suspensions or emulsions, or dry powders which are dissolved or suspended in a suitable vehicle prior to use.
Fluid unit dosage forms are prepared utilising the compound and a pyrogen-free sterile vehicle. The compound, depending on the vehicle and concentration used, can be
either dissolved or suspended in the vehicle. Solutions may be used for all forms of parenteral administration, and are panicularly used for intravenous infection. In preparing solutions the compound can be dissolved in the vehicle, the solution being made isotonic if necessary by addition of sodium chloride and sterilised by filtration through a sterile filter using aseptic techniques before filling into suitable sterile vials or ampoules and sealing. Alternatively, if solution stability is adequate, the solution in its sealed containers may be sterilised by autoclaving. Advantageously additives such as buffering, solubilising, stabilising, preservative or bactericidal, suspending or emulsifying agents and/or local anaesthetic agents may be dissolved in the vehicle. Dry powders which are dissolved or suspended in a suitable vehicle prior to use may be prepared by filling pre-sterilised drug substance and other ingredients into a sterile container using aseptic technique in a sterile area. Alternatively the drug and other ingredients may be dissolved in an aqueous vehicle, the solution is sterilised by filtration and distributed into suitable containers using aseptic technique in a sterile area. The product is then freeze dried and the containers are sealed aseptically.
Parenteral suspensions, suitable for intramuscular, subcutaneous or intradermal injection, are prepared in substantially the same manner, except that the sterile compound is suspended in the sterile vehicle, instead of being dissolved and sterilisation cannot be accomplished by filtration. The compound may be isolated in a sterile state or alternatively it may be sterilised after isolation, e.g. by gamma iπadiation.
Advantageously, a suspending agent for example polyvinylpyrrolidone is included in the composition to facilitate uniform distribution of the compound.
Compositions suitable for administration via the respiratory tract include aerosols, nebulisable solutions or microfine powders for insufflation. In the latter case, panicle size of less than 50 microns, especially less than 10 microns, is preferred. Such compositions may be made up in a conventional manner and employed in conjunction with conventional administration devices.
In a fuπher aspect there is provided a method of treating obesity or diseases associated with obesity, such as atherosclerosis, hypeπension and, especially, Type LT diabetes, in human or non-human mammals which comprises administering to the sufferer an effective, non-toxic amount of a compound of the invention.
Suitable non-human mammals are domestic mammals such as dogs and cats. The invention funher provides a compound of the invention for use as an active therapeutic substance, in paπicular for use in treating obesity or diseases associated with obesity, such as atherosclerosis, hypertension and, especially, Type LT diabetes.
The invention also provides the use of a compound of the invention in the manufacture of a medicament for treating obesity or diseases associated with obesity, such as atherosclerosis, hypeπension and, especially, Type LT diabetes.
As indicated above the invention also encompasses cosmetic treatments. Accordingly, there is also provided a compound of the invention for use in the cosmetic treatment of human or non-human mammals.
There is also provided a method for the cosmetic treatment of a human or non¬ human mammal, which treatment comprises administering an effective, non-toxic amount of a compound of the invention to a human or non-human mammal in need thereof.
Cosmetic treatment suitably includes treatment for the improvement of body appearence, such as weight reduction treatment.
The invention also extends to a cosmetic composition, comprising a compound of the invention and a carrier therefor. Compositions of the invention including cosmetic compositions are formulated using known methods, for example those described in standard text books of pharmaceutics and cosmetics, such as Harry's Cosmeticology published by Leonard Hill Books, Remington's Pharmaceutical Sciences, the British and US Pharmacopoeias.
No unexpected toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.
The following Examples illustrate the invention but do not limit it in any way.
Example 1.
Construction of DNA coding for fusion protein leptin l-167/IgG4 hinge-CH2-CH3
The gene coding for a fusion protein comprising human leptin and the hinge-CH2-CH3 region of human IgG4 is created by recombinant DNA technology, preferably by a two-step recombinant PCR method.
The human Ob' gene has been prepared synthetically based on the amino acid sequence of Zhang et al, and assembled in the pcDNA3 vector.
The cDNA encoding full length human leptin, nucleotides 1-501 is joined at the 3' end to the 5' end of the hinge-CH2-CH3 region of the cDNA coding for the human IgG4 protein, shown as nucleotides 502-1188 in the DNA sequence below. (Table 1.) The encoded protein sequence of the leptin/IgG4 chimera is given in Table 2. Leptin 1-167 (numbering as Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold & J. Friedman. Nature 372:425-432), and IgG4 hinge-CH2-CH3 168-396 (sequence as Kabat).
The fusion protein was expressed transiently in Cosl cells using the pCDN vector system, as described in Intemationai Patent Application Publication number WO 96/04388. The mature protein was exponed from the cells into the culture medium and was detected by anti-leptin antibody. It was shown to to have a size consistent with the predicted structure by Western blotting analysis under both reducing and nonreducing conditions.
Table 1. DNA sequence of ob/IgG4 chimera, 1188bp
ATGCATTGGGGAACCCTGTGCGGATTCTTGTGGCTTTGGCCCTATCTTTTCTATGTCCAA
60
GCTGTGCCCATCCAAAAAGTCCAAGATGACACCAAAACCCTCATCAAGACAATTGTCACC
120
AGGATCAATGACATTTCACACACGCAGTCAGTCTCCTCCAAACAGAAAGTCACCGGTTTG
180
GACTTCATTCCTGGGCTCCACCCCATCCTGACCCTGTCCAAGATGGACCAGACACTGGCA 240
GTCTACCAACAGATCCTCACATCGATGCCTTCCAGAAACGTGATCCAAATATCCAACGAC
300 CTGGAGAACCTCCGGGATCTTCTTCACGTGCTGGCCTTCTCTAAGAGCTGCCACTTGCCC
360
TGGGCCAGTGGCCTGGAGACCTTGGACAGCCTGGGGGGTGTCCTCGAGGCTTCAGGCTAC
420
TCCACAGAGGTGGTGGCCCTGAGCAGGCTGCAGGGGTCTCTGCAGGACATGCTGTGGCAG
480
CTGGACCTCAGCCCCGGGTGCGAGTCCAAATATGGTCCCCCATGCCCATCATGCCCAGCA 540
CCTGAATTTCTGGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTC
600
ATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCC
660
GAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCG
720
CGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG
780
GACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCATCG 840
ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTG
900 CCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGC
960
TTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTAC
1020
AAGACCACGCCTCCCGTGCTGGACTCCGACGGATCCTTCTTCCTCTACAGCAGGCTAACC
1080
GTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCT 1140
CTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAA
1188
Table 2. Amino acid sequence of leptin/IgG4 chimera, 396aa
1 MH GTLCGFL WLWPYLFYVQ AVPIQKVQDD TKTLIKTIVT RINDISHTQS
51 VSSKQKVTGL DFIPGLHPIL TLSKMDQTLA VYQQLLTSMP SRNVIQISND
101 LENLRDLLHV LAFSKSCHLP WASGLETLDS LGGVLEASGY STEVVALSRL
151 QGSLQDMLWQ LDLSPGCESK YGPPCPSCPA PEFLGGPSVF LFPPKPKDTL
201 MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR
251 VVSVLTVLHQ DWLNGKEYK CKVSNKGLPSS LEKTISKAKG QPREPQVYTL
301 PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD
351 GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLGK
Example 2.
Construction of DNA coding for fusion protein ob l-167/IgG4 hinge-CH2-CH3 PE variant The gene coding for a fusion protein comprising the human Ob' protein and the Hinge-CH2-CH3 region of human IgG4 PE (a form of IgG4 mutated as below) is created by recombinant DNA technology, preferably by a two-step recombinant PCR method.
The cDNA coding for the complete human leptin, amino acids l-167(numbering as Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold & J. Friedman. Nature 372: 425-432) is joined at the 3' end to the 5' end of the hinge-CH2-CH3 region of the cDNA coding for the human IgG4 (PE variant) protein, shown as amino acids 168-396 in the protein sequence below.
The human Ob' gene has been prepared synthetically based on the amino acid sequence of Zhang et al, and assembled in the pcDNA3 vector. The encoded protein sequence is given in Table 2.
Human IgG4 heavy chain PE variant. In IgG4 PE, residue 10 of the hinge (residue 241, Kabat numbering) is altered from serine (S) in the wild type to proline (P) and residue 5 of CH2 (residue 248, Kabat numbering) is altered from leucine (L) in the wild type to glutamate (E). Angal S., King D.J., Bodmer M.W., Turner A., Lawson A.D.G., Robeπs G., Pedley B. and Adair R., Molecular Immunology vol30ppl05-108, 1993, describe an IgG4 molecule where residue 241 (Kabat numbering) is altered from serine to proline. This change increases the serum half-life of the IgG4 molecule.
The IgG4 PE variant was created using PCR mutagenesis on the synthetic human IgG4 heavy chain cDNA. The sequence of the IgG4 PE variant is described in Table 1. The residues of the IgG4 nucleotide sequence which were altered to make the PE variant are as follows: referring to Table 1 : residue 322 has been altered to "C" in the PE variant from "T" in the wild type; residue 333 has been altered to "G" in the PE variant from "A" in the wild type; and residues 343-344 have been altered to "GA" in the PE variant from "CT" in the wild type.
The fusion protein was expressed transiently in Cosl cells using the pCDN vector system, as described in International Patent Application Publication number WO 96/04388. The mature protein was exponed from the cells into the culture medium and was detected by anti-leptin antibody. It was shown to to have a size consistent with the predicted structure by Western blotting analysis under both reducing and nonreducing conditions.
Table 3. DNA sequence of IgG4 PE variant, 984bp
SEQ ID No: 1
GCTAGTACCAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAG
60
AGCACgGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCG 120
TGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCA
180 GGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACC
240 TACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCC
300 AAATATGGTCCCCCATGCCCAcCATGCCCAGCgCCTGAaTTtgaGGGGGGACCATCAGTC
360
TTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACG 420
TGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGAT
480 GGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC
540 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAG
600 TGCAAGGTCTCCAACAAAGGCCTCCCGTCaTCgATCGAGAAAACCATCTCCAAAGCCAAA
660
GGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAG 720
AACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAG
780 TGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCC
840 GACGGaTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGG
900 AATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGC
960 CTCTCCCTGTCTCTGGGTAAATGA 984
Table3A: DNAsequenceofob/IgG4PEchimera, 1188bp ATGCATTGGGGAACCCTGTGCGGATTCTTGTGGCTTTGGCCCTATCTTTTCTATGTCCAA
60 GCTGTGCCCATCCAAAAAGTCCAAGATGACACCAAAACCCTCATCAAGACAATTGTCACC
120
AGGATCAATGACATTTCACACACGCAGTCAGTCTCCTCCAAACAGAAAGTCACCGGTTTG 180
GACTTCATTCCTGGGCTCCACCCCATCCTGACCCTGTCCAAGATGGACCAGACACTGGCA
240 GTCTACCAACAGATCCTCACATCGATGCCTTCCAGAAACGTGATCCAAATATCCAACGAC
300
CTGGAGAACCTCCGGGATCTTCTTCACGTGCTGGCCTTCTCTAAGAGCTGCCACTTGCCC
360
TGGGCCAGTGGCCTGGAGACCTTGGACAGCCTGGGGGGTGTCCTCGAGGCTTCAGGCTAC 420
TCCACAGAGGTGGTGGCCCTGAGCAGGCTGCAGGGGTCTCTGCAGGACATGCTGTGGCAG
480 CTGGACCTCAGCCCCGGGTGCGAGTCCAAATATGGTCCCCCATGCCCAcCATGCCCAGCg
540 CCTGAATTTGAGGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTC
600 ATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCC
660
GAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCG 720
CGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG
780 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCATCG
840 ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTG
900 CCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGC
960
TTCTACCCCAGCGACATCGCCGTGGAGTTGGAGAGCAATGGGCAGCCGGAGAACAACTAC 1020
AAGACCACGCCTCCCGTGCTGGACTCCGACGGATCCTTCTTCCTCTACAGCAGGCTAACC
1080 GTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCT
1140 CTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAA
1188
Table 4: Amino acid sequence of ob l-167/IgG4 hinge-CH2-CH3 PE variant chimera 396aa
SEQ LD No: 2
1 MHWGTLCGFL WLWPYLFYVQ AVPIQKVQDD TKTLIKTIVT RINDISHTQS
51 VSSKQKVTGL DFIPGLHPIL TLSKMDQTLA VYQQLLTSMP SRNVIQISND
101 LENLRDLLHV LAFSKSCHLP WASGLETLDS LGGVLEASGY STEVVALSRL
151 QGSLQDMLWQ LDLSPGCESK YGPPCPPCPA PEFEGGPSVF LFPPKPKDTL
201 MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR
251 VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS LEKTISKAKG QPREPQVYTL
301 PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD
351 GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLGK
Example 3.
Construction of DNA coding for fusion protein leptin 1-167/IgGl hinge-CH2-CH3
The gene coding for a fusion protein comprising human leptin and the hinge-CH2-CH3 region of human IgGl is created by recombinant DNA technology, preferably by a two-step recombinant PCR method.
The human 'ob' gene has been prepared synthetically based on the amino acid sequence of Zhang et al, and assembled in the pcDNA3 vector.
The cDNA encoding full length human leptin, nucleotides 1-501 is joined at the 3' end to the 5' end of the hinge-CH2-CH3 region of the cDNA coding for the human IgGl protein, shown as nucleotides 502-1197 in the DNA sequence below. (Table 1.)
The encoded protein sequence of the leptin/IgGl chimera is given in Table 2. Leptin 1-167 (numbering asY. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold & J. Friedman. Nature 372: 425-432) and IgGl hinge-CH2-CH3 shown as amino acids 168-399.
The gene coding for the human IgGl contains a number of nucleotide substitutions compared to the IgGl molecule described by Ellison J.W., Berson B.J. and Hood L.E., Nucleic Acids Research vol 10 No. 13 pp4071-4079, 1982. The IgGl nucleotides which differ from the Ellison J.W. et al published sequence and the resulting amino acid substitutions are as follows ( nucleotide numbering as in table 1)
nucleotide 513 is "G" in this variant compared to "T" in the Ellison et al sequence (silent mutation)
nucleotides 514-516 are "GCC" in this variant compared to "TGT" in the Ellison et al sequence (resulting in substitution of Ala for Cys in this variant, amino acid 172 in table 2)
nucleotide 759 is "T" in this variant compared to "G" in the Ellison et al sequence
(silent mutation)
nucleotide 924 is "G" in this variant compared to "T" in the Ellison et al sequence (resulting in substitution of Glu for Asp in this variant, amino acid 308 in table2)
nucleotide 928 is "A" in this variant compared to "C" in the Ellison et al sequence (resulting in substitution of Met for Val in this variant, amino acid 310 in table 2)
nucleotide 1077 is "T" in this variant compared to "C" in the Ellison et al sequence (silent mutation)
nucleotide 1197 is "G" in this variant compared to "A" in the Ellison et al sequence (silent mutation)
The fusion protein was expressed transiently in Cosl cells using the pCDN vector system, as described in International Patent Application Publication number WO 96/04388.
The mature protein was exponed from the cells into the culture medium and was detected by anti-leptin antibody. It was shown to to have a size consistent with the predicted structure by Western blotting analysis under both reducing and nonreducing conditions.
Table 5. DNA sequence of ob/IgGl chimera 1197bp
ATGCATTGGGGAACCCTGTGCGGATTCTTGTGGCTTTGGCCCTATCTTTTCTATGTCCAA
60
GCTGTGCCCATCCAAAAAGTCCAAGATGACACCAAAACCCTCATCAAGACAATTGTCACC
120
AGGATCAATGACATTTCACACACGCAGTCAGTCTCCTCCAAACAGAAAGTCACCGGTTTG 180
GACTTCATTCCTGGGCTCCACCCCATCCTGACCCTGTCCAAGATGGACCAGACACTGGCA
240 GTCTACCAACAGATCCTCACATCGATGCCTTCCAGAAACGTGATCCAAATATCCAACGAC
300
CTGGAGAACCTCCGGGATCTTCTTCACGTGCTGGCCTTCTCTAAGAGCTGCCACTTGCCC
360
TGGGCCAGTGGCCTGGAGACCTTGGACAGCCTGGGGGGTGTCCTCGAGGCTTCAGGCTAC
420
TCCACAGAGGTGGTGGCCCTGAGCAGGCTGCAGGGGTCTCTGCAGGACATGCTGTGGCAG 480
CTGGACCTCAGCCCCGGGTGCGAGCCCAAATCGGCCGACAAAACTCACACATGCCCACCG
540 TGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG
600
GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCAC
660
GAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAG
720
ACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTC 780
CTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTC
840 CCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTG
900
TACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCG
960
GTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG
1020 AACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGC
1080
AAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATG
1140
CATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAG
1197
Table 6. Amino acid sequence of leptin/IgGl chimera, 399aa
1 MHWGTLCGFL WLWPYLFYVQ AVPIQKVQDD TKTLIKTIVT RINDISHTQS
51 VSSKQKVTGL DFIPGLHPIL TLSKMDQTLA VYQQLLTSMP SRNVIQISND
101 LENLRDLLHV LAFSKSCHLP WASGLETLDS LGGVLEASGY STEVVALSRL
151 QGSLQDMLWQ LDLSPGCEPK SADKTHTCPP CPAPELLGGP SVFLFPPKPK 201 DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
251 TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKΗSK AKGQPREPQV
301 YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL
351 DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
Example 4.
Construction of DNA coding for fusion protein leptin 1-167/IgGl hinge-CH2-CH3 GT linker variant
The gene coding for a fusion protein comprising human leptin and the hinge-CH2-CH3 region of human IgGl with a 'GT' two amino acid linker between the two parts of the fusion molecule, is created by recombinant DNA technology, preferably by a two-step recombinant PCR method.
The human 'ob' gene has been prepared synthetically based on the amino acid sequence of Zhang et al, and assembled in the pcDNA3 vector.
The cDNA encoding the full length human leptin (nucleotides 1-501) is joined at the 3' end to the 5' end of the hinge-CH2-CH3 region of the IgGl cDNA (nucleotides 508-1203). The two amino acid linker between the two pans of the fusion is encoded by the nucleotide sequence GGTACC (502-507). See Table 1. The encoded protein sequence of the leptin/LgG 1 (GT) chimera is given in Table 2. Lept
(numbering asY. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold & J. Friedman. Nature 372:425-432), followed by the GT linker (168-169) and IgGl H-CH2-CH3 170-401.
The gene coding for the human IgGl contains a number of nucleotide substitutions compared to the IgGl molecule described by Ellison J.W., Berson B.J. and Hood L.E., Nucleic Acids Research vol 10 No. 13 pp4071-4079, 1982. The IgGl nucleotides which differ from the Ellison J.W. et al published sequence and the resulting amino acid substitutions are as follows ( nucleotide numbering as in table 1)
nucleotide 519 is "G" in this variant compared to "T" in the Ellison et al sequence (silent mutation)
nucleotides 520-522 are "GCC" in this variant compared to "TGT" in the Ellison et al sequence (resulting in substitution of Ala for Cys in this variant, amino acid 174 in table 2)
nucleotide 759 is "T" in this variant compared to "G" in the Ellison et al sequence (silent mutation)
nucleotide 924 is "G" in this variant compared to "T" in the Ellison et al sequence (resulting in substitution of Glu for Asp in this variant, amino acid 308 in table2)
nucleotide 928 is "A" in this variant compared to "C" in the Ellison et al sequence (resulting in substitution of Met for Val in this variant, amino acid 310 in table 2)
nucleotide 1077 is "T" in this variant compared to "C" in the Ellison et al sequence
(silent mutation)
nucleotide 1197 is "G" in this variant compared to "A" in the Ellison et al sequence
(silent mutation) The fusion protein was expressed transiently in Cosl cells using the pCDN vector system, as described in International Patent Application Publication number WO 96/04388. The mature protein was exponed from the cells into the culture medium and was detected by anti-leptin antibody. It was shown to to have a size consistent with the predicted structure by Westem blotting analysis under both reducing and nonreducing conditions.
Table 7. DNA sequence of ob/IgGl'GT' chimera , 1203bp
ATGCATTGGGGAACCCTGTGCGGATTCTTGTGGCTTTGGCCCTATCTTTTCTATGTCCAA
60
GCTGTGCCCATCCAAAAAGTCCAAGATGACACCAAAACCCTCATCAAGACAATTGTCACC
120
AGGATCAATGACATTTCACACACGCAGTCAGTCTCCTCCAAACAGAAAGTCACCGGTTTG 180
GACTTCATTCCTGGGCTCCACCCCATCCTGACCCTGTCCAAGATGGACCAGACACTGGCA
240 GTCTACCAACAGATCCTCACATCGATGCCTTCCAGAAACGTGATCCAAATATCCAACGAC
300
CTGGAGAACCTCCGGGATCTTCTTCACGTGCTGGCCTTCTCTAAGAGCTGCCACTTGCCC
360
TGGGCCAGTGGCCTGGAGACCTTGGACAGCCTGGGGGGTGTCCTCGAGGCTTCAGGCTAC
420
TCCACAGAGGTGGTGGCCCTGAGCAGGCTGCAGGGGTCTCTGCAGGACATGCTGTGGCAG 480
CTGGACCTCAGCCCCGGGTGCGGTACCGAGCCCAAATCGGCCGACAAAACTCACACATGC
540 CCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAA
600
CCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTG
660
AGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAAT
720
GCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTC 780
ACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAA
840 GCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCA
900
CAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACC
960
TGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAG
1020
CCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTC 1080
TATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCC
1140 GTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT
1200
AAG 1203
Table 8. Amino acid sequence of leptin/IgGl 'GT' chimera, 401aa
1 MHWGTLCGFL WLWPYLFYVQ AVPIQKVQDD TKTLIKTIVT RINDISHTQS
51 VSSKQKVTGL DFIPGLHPIL TLSKMDQTLA VYQQILTSMP SRNVIQISND
101 LENLRDLLHV LAFSKSCHLP WASGLETLDS LGGVLEASGY STEVVALSRL
151 QGSLQDMLWQ LDLSPGCGTE PKSADKTHTC PPCPAPELLG GPSVFLFPPK 201 PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY
251 NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPLEKTI SKAKGQPREP
301 QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP
351 VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG
401 K
Claims
1. Chimeric leptin or a chimeric mutant or derivative of leptin.
2. A chimera according to claim 1, wherein the leptin is human leptin.
3. A chimera according to claim 1 or claim 2, wherein the leptin or a mutant or variant thereof is fused to a human immunoglobulin domain or a mutant or variant thereof.
4. A chimera according to any one of claims 1 to 3, wherein the chimeric protein comprises one human immunoglobulin domain.
5. A chimera according to claim 4, wherein the human immunoglobulin domain is fused to the C-terminus of leptin.
6. A chimera according to any one of claims 1 to 4, which comprises a human immunoglobulin Fc domain.
7. A chimera according to claim 6, wherein the human immunoglobulin Fc domain is an IgG4PE variant, an IgG4, IgGl or an IgGlGT variant, in particular the hinge-CH2-
CH3 region in each case.
8. A chimera according to claim 7, wherein the variant a hinge-CH2-CH3 varianL
9. Chimeric leptin selected from the list consisting of: leptin l-167/IgG4 hinge-CH2-CH3; leptin l-167/IgG4 hinge-CH2-CH3 PE variant; leptin 1-167/IgGl hinge-CH2-CH3; and leptin 1-167/IgGl hinge-CH2-CH3 GT linker variant.
10. A process for preparing a chimera according to any one of claims 1 to 8, which process comprises expressing DNA encoding said compound in a recombinant host cell and recovering the product.
11. A process according to claim 10, which process comprises the steps of: i) preparing a replicable expression vector capable, in a host cell, of expressing a DNA polymer comprising a nucleotide sequence that encodes said chimera; ii) transforming a host cell with said vector; iii) culturing said transformed host cell under conditions permitting expression of said DNA polymer to produce said chimera; and iv) recovering said chimera.
12. A DNA polymer comprising a nucleotide sequence that encodes a chimera according to any one of claims 1 to 8.
13. A vector which comprises a DNA polymer according to claim 12.
14. A host cell transformed or transfected with a DNA polymer according to claim 12 or a vector according to claiml3.
15. A pharmaceutical composition comprising a chimera as claimed in claim 1 and a pharmaceutically acceptable carrier.
16. A chimera according to claim 1, for use as an active therapeutic substance.
17. A chimera according to claim 1, for use in the treatment of obesity or diseases associated with obesity.
18. A method for the treatment of obesity or diseases associated with in human or non-human mammal, which method comprises administering to the sufferer an effective, non-toxic amount of a chimera as claimed in claim 1.
19. A chimera as claimed in claim 1 , for use in the cosmetic treatment of human or non-human mammals.
20. A method for the cosmetic treatment of a human or non-human mammal, which treatment comprises administering an effective, non-toxic amount of a compound of the invention to a human or non-human mammal in need thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9511935.0A GB9511935D0 (en) | 1995-06-13 | 1995-06-13 | Novel compound |
GB9511935 | 1995-06-13 | ||
PCT/GB1996/001388 WO1997000319A2 (en) | 1995-06-13 | 1996-06-11 | Chimeric leptin fused to immunoglobulin domain and use |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0832219A2 true EP0832219A2 (en) | 1998-04-01 |
Family
ID=10775951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96917584A Withdrawn EP0832219A2 (en) | 1995-06-13 | 1996-06-11 | Chimeric leptin fused to immunoglobulin domain and use |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0832219A2 (en) |
JP (1) | JPH11507547A (en) |
AU (1) | AU6011096A (en) |
CA (1) | CA2224646A1 (en) |
GB (1) | GB9511935D0 (en) |
WO (1) | WO1997000319A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7291458B2 (en) | 1998-07-28 | 2007-11-06 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Leptin-mediated gene-induction |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6310034B1 (en) | 1993-05-21 | 2001-10-30 | Ut-Battelle, Llc | Agouti polypeptide compositions |
US6429290B1 (en) | 1994-08-17 | 2002-08-06 | The Rockefeller University | OB polypeptides, modified forms and derivatives |
US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
PT866720E (en) * | 1995-11-22 | 2004-06-30 | Amgen Inc | PROTEIN OB TO INCREASE MASS OF MOLE TISSUE |
AU769250B2 (en) * | 1995-12-27 | 2004-01-22 | Genentech Inc. | OB protein derivatives having prolonged half-life |
US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
CA2238307A1 (en) * | 1995-12-27 | 1997-07-10 | Genentech, Inc. | Ob protein derivatives having prolonged half-life |
US7074397B1 (en) | 1996-01-08 | 2006-07-11 | Genentech, Inc. | Method for enhancing proliferation or differentiation of a cell using ob protein |
US6541604B1 (en) | 1996-01-08 | 2003-04-01 | Genentech, Inc. | Leptin receptor having a WSX motif |
US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
AU770897B2 (en) * | 1996-12-20 | 2004-03-04 | Amgen, Inc. | OB fusion protein compositions and methods |
NZ514145A (en) * | 1996-12-20 | 2003-08-29 | Amgen Inc | OB fusion protein compositions and methods |
WO1998036763A1 (en) * | 1997-02-25 | 1998-08-27 | Eli Lilly And Company | Treatment of infertility with leptin receptor ligands |
JP4086908B2 (en) * | 1997-04-17 | 2008-05-14 | アムジエン・インコーポレーテツド | Compositions and methods comprising conjugates of stable and active human OB protein and antibody Fc chains |
AU2002300605B8 (en) * | 1997-04-17 | 2006-02-09 | Amgen Inc. | Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods |
US20020019352A1 (en) * | 1997-04-17 | 2002-02-14 | David N. Brems | Stable, active, human ob protein compositions and methods |
US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
AU8182298A (en) * | 1997-07-10 | 1999-02-08 | Beth Israel Deaconess Medical Center | Recombinant erythropoietin / immunoglobulin fusion proteins |
US6187564B1 (en) | 1997-07-10 | 2001-02-13 | Beth Israel Deaconess Medical Center | DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics |
US6242570B1 (en) | 1997-07-10 | 2001-06-05 | Beth Israel Deaconess Medical Center | Production and use of recombinant protein multimers with increased biological activity |
CZ20003099A3 (en) * | 1998-02-25 | 2002-04-17 | Lexigen Pharmaceuticals Corporation | Enhancing the circulating half-life of antibody-based fusion proteins |
CA2356401A1 (en) * | 1999-01-07 | 2000-07-13 | Lexigen Pharmaceuticals, Corp. | Expression and export of anti-obesity proteins as fc fusion proteins |
WO2000068376A1 (en) * | 1999-05-07 | 2000-11-16 | Genentech, Inc. | Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same |
WO2001025428A1 (en) * | 1999-10-01 | 2001-04-12 | Eli Lilly And Company | A novel human leptin homolog |
CA2399832C (en) * | 2000-02-11 | 2011-09-20 | Stephen D. Gillies | Enhancing the circulating half-life of antibody-based fusion proteins |
EP1612221A3 (en) | 2000-05-22 | 2008-07-23 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Receptor-based interaction trap |
US7235629B2 (en) | 2000-11-14 | 2007-06-26 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Functional fragment of the leptin receptor |
RU2363707C2 (en) * | 2001-02-19 | 2009-08-10 | Мерк Патент Гмбх | Artificial proteins with lowered adjuvanticity |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
US7737260B2 (en) | 2003-11-13 | 2010-06-15 | Hanmi Pharm. Co., Ltd | Protein complex using an immunoglobulin fragment and method for the preparation thereof |
AU2004251145C1 (en) | 2003-06-12 | 2011-04-14 | Eli Lilly And Company | GLP-1 analog fusion proteins |
SI1641483T1 (en) * | 2003-06-12 | 2008-08-31 | Lilly Co Eli | Fusion proteins |
JP2007531707A (en) | 2003-10-15 | 2007-11-08 | ピーディーエル バイオファーマ, インコーポレイテッド | Modification of Fc fusion protein serum half-life by mutagenesis of heavy chain constant region positions 250, 314 and / or 428 of IG |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
WO2005066348A2 (en) | 2004-01-05 | 2005-07-21 | Emd Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
US7423113B2 (en) | 2004-08-25 | 2008-09-09 | Vib Vzw | Leptin antagonist |
EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
DE602005015257D1 (en) * | 2004-12-22 | 2009-08-13 | Lilly Co Eli | |
WO2007085814A1 (en) * | 2006-01-24 | 2007-08-02 | Domantis Limited | Fusion proteins that contain natural junctions |
MX2011011044A (en) | 2009-04-22 | 2011-11-04 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites. |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2120949T4 (en) * | 1990-06-28 | 2011-12-29 | Sanofi-Aventis Deutschland Gmbh 50% | FUSION PROTEINS WITH LOTS OF IMMUNOGLOBULINS, THEIR PREPARATION AND EMPLOYMENT. |
US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
GB9509164D0 (en) * | 1995-05-05 | 1995-06-28 | Smithkline Beecham Plc | Novel compounds |
WO1996035787A1 (en) * | 1995-05-08 | 1996-11-14 | Chiron Corporation | Nucleic acids for treating obesity |
-
1995
- 1995-06-13 GB GBGB9511935.0A patent/GB9511935D0/en active Pending
-
1996
- 1996-06-11 JP JP9502784A patent/JPH11507547A/en active Pending
- 1996-06-11 CA CA002224646A patent/CA2224646A1/en not_active Abandoned
- 1996-06-11 AU AU60110/96A patent/AU6011096A/en not_active Abandoned
- 1996-06-11 EP EP96917584A patent/EP0832219A2/en not_active Withdrawn
- 1996-06-11 WO PCT/GB1996/001388 patent/WO1997000319A2/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9700319A2 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7291458B2 (en) | 1998-07-28 | 2007-11-06 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Leptin-mediated gene-induction |
Also Published As
Publication number | Publication date |
---|---|
CA2224646A1 (en) | 1997-01-03 |
JPH11507547A (en) | 1999-07-06 |
WO1997000319A3 (en) | 1997-04-10 |
AU6011096A (en) | 1997-01-15 |
WO1997000319A2 (en) | 1997-01-03 |
GB9511935D0 (en) | 1995-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0832219A2 (en) | Chimeric leptin fused to immunoglobulin domain and use | |
JP7227951B2 (en) | Interleukin-2 muteins for proliferation of regulatory T cells | |
US5783181A (en) | Therapeutic uses of fusion proteins between mutant IL 4/IL13 antagonists and immunoglobulins | |
EP2507267B1 (en) | Compositions and methods for increasing serum half-life of fc fusion proteins | |
EP1606318B1 (en) | Improved fc fusion proteins | |
AU720943B2 (en) | Receptor protein designated 2F1 | |
WO1996004388A1 (en) | Novel compounds | |
Hahne et al. | Characterization of the non-functional Fas ligand of gld mice | |
KR20160034404A (en) | Stabilization of fc-containing polypeptides | |
JPH06315383A (en) | Soluble ligand for cd 40 | |
JPH0753594A (en) | P-40 homodimer of interleukin 12 | |
JPH08507676A (en) | Method for preparing soluble oligomeric protein | |
NZ260146A (en) | Tumour necrosis factor (tnfalpha) muteins and their production and use | |
KR19990063653A (en) | Chemokine inhibitors | |
US20240101627A1 (en) | Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof | |
CA2339968A1 (en) | Dcr5, a bmp-binding protein, and applications thereof | |
WO2022117044A1 (en) | Glp-1/gcg dual receptor agonist polypeptide and fusion protein thereof | |
AU2022263441A1 (en) | Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof | |
CA2132859A1 (en) | Decorin fragments and methods of inhibiting cell regulatory factors | |
NO318912B1 (en) | Interferon alpha / beta binding protein, as well as its preparation and use | |
AU2140699A (en) | Novel compounds | |
JPS638398A (en) | Physiologically active polypeptide | |
KR20040009997A (en) | Concatameric immunoadhesin | |
AU1196402A (en) | Novel compounds | |
WO1997045448A1 (en) | An interleukin-5 antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19971216 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): BE CH DE DK ES FR GB IT LI NL |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20030103 |